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Abstract
The determination of prognosis for B-Non-
Hodgkin’s  lymphoma  (NHL)  is  known  to  be
related to the multiple differences in tumor cell
biology. Bcl-2 and Bcl-6 are two markers linked
to germinal center B cells. Both markers are
thought  to  have  an  effect  on  prognosis  of
mature  B-cell  neoplasms.  Forty-four  patients
with chronic B-cell neoplasm were included;
Bcl-2 and Bcl-6 expression by immunohisto-
chemistry  was  examined.  Bcl-2  protein  was
positive in 36.4% (16 of 44) of cases (62.5% of
follicular lymphoma, 16.7% of mantle cell lym-
phoma  and  30%  of  diffuse  large  B-cell  lym-
phoma);  the  positive  group  implying  a  bad
prognostic effect of the marker in NHL. Bcl-6
was positive in 13.6% (6 of 44) of cases (11.1%
of mantle cell lymphoma and 40% of diffuse
large  B-cell  lymphoma)  and  its  positivity
implies a better disease course. Bcl-2 and Bcl-
6 can be used as prognostic marker in NHL.
Introduction
The determination of prognosis for each of
the Non-Hodgkin’s lymphoma (NHL) variants
is known to be related to the multiple differ-
ences  in  tumor  cell  biology  (cytogenetics,
immunophenotype,  growth  fraction,  cytokine
production) found within each of the specific
disease variants.1-3
Bcl-2 and Bcl-6 are two markers linked to
germinal center B cells. The Bcl-2 gene, locat-
ed at chromosome 18q21, encodes for a 25kd
protein  located  mainly  in  the  mitochondrial
membrane. This Bcl-2 protein is an anti-apop-
tosis factor that is important in normal B-cell
development and differentiation. Bcl-2 overex-
pression  provides  a  survival  advantage  for
malignant B cells and is thought to play a crit-
ical role in resistance to chemotherapy.4
The  Bcl-6  gene,  located  at  chromosome
3q27, encodes a 79kd DNA binding protein and
transcriptional  repressor  that  appears  to  be
involved in mediating growth suppression.5 In
lymphoid  tissues,  the  Bcl-6  protein  is
expressed in germinal center B cells in second-
ary follicles in both the dark (centroblast-rich)
and light (centrocyte-rich) zones.6
Immunohistochemical studies of the prog-
nostic value of Bcl-6 expression led to discor-
dant results. Some supported its ability to pre-
dict for a better overall survival rate, whereas
others found no difference in overall survival
rates.7
Materials and Methods
Subjects
Forty-four  newly  diagnosed  B-NHL  adult
patients attending the hematology unit of the
clinical  pathology  department,  Ain  Shams
University took part in the study. Patients were
recruited to the study on the basis of clinical
and laboratory criteria of B-NHL. All patients
were subjected to clinical sheet details, com-
plete  blood  count  with  examination  of  PB
smears  stained  with  Leishman  stain,  bone
marrow  aspiration,  bone  marrow  trephine
biopsy, immunophenotyping using lymphopro-
liferative  disorder  panel  (CD19,  CD5,  CD10,
CD11c,  CD20,  CD22,  CD23,  CD38,  CD79b,
FMC7, CD103, CD25, kappa and lambda light
chains). Bcl-2 and Bcl-6 immunostaining was
performed  on  fixed  bone  marrow  trephine
biopsy specimen.
The diagnosis of NHL was confirmed by tis-
sue biopsy in 40 patients (lymph node biopsy
in 38 patients and liver biopsy in 2 patients). In
the remaining 4 patients, bone marrow was
the first diagnostic material. The 44 NHL cases
comprised 18 mantle cell lymphomas (MCL),
16 follicular lymphomas (FL) and 10 diffuse
large B-cell lymphomas (DLBCL).
Methods
Two milliliter peripheral blood samples were
collected in a sterile EDTA containing vaccu-
tainers for CBC and immunophenotyping. BM
aspiration was withdrawn, a few drops were
put on glass slides for morphological examina-
tion  and  1  mL  into  sterile  EDTA  containing
vacutainers  for  immunophenotyping.  BM
trephine core biopsy was obtained and trans-
ferred immediately in a sterile plastic cup con-
taining aldehyde solution fixative.
Immunohistochemistry
Fixation was performed for 24 h; decalcifica-
tion of the core was performed using disodium
ethylene-diamine-tetra  acetic  acid  for  48  h.
This was followed by passing the core in serial
concentrations  of  ethyl  alcohol  (50%,  70%,
85%, 90%, and 100%) ending with xyelene then
wax followed by paraffin embedding.
Serial  3-ʼm  sections  were  cut  from  the
paraffin block, mounted on positively charged
slides  and  dried  overnight  in  a  60°C  oven.
Sections were then deparaffinized in xylene
for 24 h and hydrated in a descending grades of
alcohol;  100%,  90%,  85%  and  70%.  Antigen
unmasking was performed by heat induced an
epitope retrieval method by placing the slides
in a plastic Coplin jar filled with citric acid
buffer so that the solution covers the slides,
then placing the jar in a microwave at 800Watt
for 20 min (divided into 4 cycles 5 min each).
The  Coplin  jar  was  then  removed  from  the
oven and allowed to cool for 15 min.
Slides were placed in a humidified chamber
and  rinsed  three  times  in  phosphate  buffer
saline (PBS). Endogenous peroxidase activity
was blocked by incubation of the tissue section
with  3%  hydrogen  peroxide  in  water  for  30
min. After washing, the tissue sections were
then incubated with the primary monoclonal
antibody, ready to use Bcl-2 and 1:10 dilution
in Bcl-6. Two hundred ʼl of the monoclonals
were added for 1 h at room temperature with
Bcl-2 and overnight at 4°C with Bcl-6.
The Streptavidin biotin method was used as
a  detection  kit  (LSAB2,  Dako,  Denmark).
Tissue sections were incubated with biotiny-
lated secondary antibody for 40 min, then with
Streptavidin  conjugated  enzyme  for  30  min
during  which  the  3,3’  diaminobenzidine
(DAB) substrate chromogen was freshly pre-
pared then added onto the tissue section for 10
min in the dark.
The sections were counterstained in Meyer
hematotoxylin,  dehydrated,  then  put  in  xye-
lene and cover-slipped by DPX mount media
and examined under a light microscope.
The positivity of the immunostaining was
detected  by  percentage  of  positive  cells  and
intensity of staining. For Bcl-2 the positivity
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cut off was considered when the reactivity of
lymphoma cells with antibodies was more than
20%8 and was more than 10% for Bcl-6.9
The pattern of staining was also considered.
For Bcl-2, membranous and cytoplasmic pat-
terns were considered positive. For Bcl-6, pos-
itivity was detected if the pattern of staining
was unclear.
Treatment regimen
Patients  with  NHL  were  treated  with
chemotherapy  protocols  with  or  without
regional radiation therapy. The used therapeu-
tic  protocol  was  CHOP  regimen;  cyclophos-
phamide 650 mg/m2 day, vincristine 1.4 mg/m2
up to 2 mg/m2 and doxorubicin 40 mg/m2 were
given in day one whereas prednisone in a dose
of 40 mg/m2 was administrated from day 1 till
day 5. Cycles were repeated at intervals of 3-4
weeks according to the tumor volume and per-
formance  status  of  patients.  Rituximab  was
added  to  CHOP  (R-CHOP)  for  B-cell  lym-
phomas with aggressive histology.10,11
Follow up
The follow-up strategy used to assess remis-
sion  included  history,  physical  examination,
serum LDH and CBC after 2-4 cycles according
to the International Workshop Group (IWG) cri-
teria.12,13 Follow-up  ranged  from  12  to  30
months  with  a  mean  of  19.5±0.7  months.
Response to therapy was assessed at the end of
induction  and  complete  remission  (CR)  was
defined as the disappearance of all physical and
radiographic evidence of lymphoma for at least
four weeks after systemic chemotherapy and/ or
radiation.14 In addition, patients with initial BM
involvement were required to have clearing (as
determined by repeated aspiration and biopsy)
to be categorized as complete responders. Non-
responders included patients in partial remis-
sion where a reduction in the size of measura-
ble lesions by at least 50% occurred with no new
lesions appearing and resistant cases who had
no response to the used chemotherapeutic reg-
imen.  Relapse  was  determined  as  the  recur-
rence of lymphoma in patients who had been in
CR for at least four weeks.12
Statistical analysis
Data were analyzed using a social science
statistical package (SPSS version 15.0.1). The
following  tests  were  performed:  descriptive
statistics including quantitative data (mean ±
standard deviation (SD) for parametric, and in
the form of median and range in non-paramet-
ric results), qualitative data (number and per-
centage),  analytical  statistics  including  ˇ2,
Fisher’s exact test, Wilcoxon Rank-sum test (Z-
value) and quantitative parametric data was
analyzed using Student’s t-test (t-value). The
overall survival (OS) and disease-free survival
(DFS)  rates  along  with  standard  error  (SE)
were  estimated  using  the  Kaplan-Meier
method and comparison between groups was
made using a log rank test. P values ≤0.05 and
≤0.01 were considered significant and highly
significant, respectively, in all analyses.
Results
There were 26 males and 18 females with a
male to female ratio 1.4:1.0. Ages ranged from
20  to  70  years  old  with  a  mean  of  45±15.2
years. The results of this study are summa-
rized in Tables 1-3 and Figures 1-5.
Bcl-2 protein was positive in 36.4% (16 of
44) of cases with the most frequent expression
in the FL group (P=0.019); 62.5% of FL, 16.7%
of MCL and 30% of DLBCL. Bcl-6 was positive
in 13.6% (6 of 44) of cases with the most fre-
quent  expression  in  the  DLBCL  group
(P=0.014) (11.1% of MCL and 40% of DLBCL)
(Table 1).
Relation of Bcl-2 protein
expression to clinical and laboratory
prognostic factors 
On comparing Bcl-2 expression with various
prognostic parameters, a statistically signifi-
cant difference was obtained in platelets count
in  which  75%  of  Bcl-2  positive  cases  were
thrombocytopenic (P=0.001). A higher serum
LDH serum level was detected in Bcl-2 positive
cases compared to Bcl-2 negative group and
the  difference  was  statistically  significant
(P=0.004). On the other hand, no statistical
significance was found as regards age, stag-
ing,  total  leukocytic  count,  hemoglobin  level
and  pattern  of  BM  infiltration  (Table  2  and
Figure1).
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Table 1. Details of Bcl-2 and Bcl-6 expression in different groups of chronic B cell neo-
plasms.
N. of cases Bcl-2 positive n (%) Bcl-6 positive n (%)
FL 16 10 (62.5) 0 (0)
MCL 18 3 (16.7) 2 (11.1)
DLBCL 10 3 (30) 4 (40)
Total 44 16 (36.4) 6 (13.6)
Table 2. Comparing Bcl-2 expression and prognostic parameters in NHL group
Parameter Bcl-2 positive Bcl-2 negative P Significance
N. cases % cases N. cases % cases
Age (mean) ≥45 yrs 12 75 16 57.1 0.236 NS
<45 yrs 4 25 12 42.9
Sex (mean) M 10 62.5 16 57.1 0.728 NS
F6 37.5 12 42.9
Hb g/dL (mean) ≥10 8 50 14 50 1 NS
<10 8 50 14 50
Plt ﾥ109/L (mean) ≥150  4 25 22 78.6 0.001 HS
<150  12 75 6 21.4
TLC ﾥ109/L (mean) ≥8  8 50 6 21.4 0.052 NS
<8  8 50 22 78.6
LDH IU/L (mean) ≥500  14 87.5 12 42.9 0.004 HS
<500  2 12.5 16 57.1
Stage I0 0 6 21.4 0.239 NS
II 2 12.5 4 14.3
III 6 37.5 8 28.6
IV 8 50 10 35.7
Pattern  Diffuse  4 25 2 7.2 0.36 NS
Patchy  4 25 10 35.7
Interstitial  2 12.5 6 21.4
Mixed  6 37.5 10 35.7
Therapeutic Responders 2 12.5 18 64.3 0.001 HS
response Non-responders 14 87.5 10 35.7
Clinical Complete remission 2 12.5 22 78.6 0.001 HS
outcome Relapse  14 87.5 6 21.4
Fate  Alive  7 43.8 24 85.7 0.003 HS
Death  9 56.2 4 14.3
S, significant; NS, non-significant; TLC, total leukocytic count; Hb, hemoglobin; Plts, platelets; BML, bone marrow lymphocytes; LDH, lactate
dehydrogenase.[page 82] [Hematology Reports 2011; 3:e26]
Impact of Bcl-2 protein expression
on response to therapy and clinical
outcome 
This study showed that 87.5% of patients with
positive  Bcl-2  protein  expression  significantly
developed  resistance  to  the  therapeutic  regi-
mens adopted at the end of induction (P=0.001).
Interestingly, these patients also displayed a poor
clinical  outcome  experiencing  higher  relapse
and mortality rates than their negative counter-
parts (P=0.001 and P=0.003, respectively).
Bcl-2 expression in relation to
patients’ survival
Kaplan-Meier survival analysis revealed sig-
nificantly shorter OS and DFS times in B-NHL
patients  with  Bcl-2  protein  expression
(P<0.05). The estimated 30-month OS survival
Article
Table 3. Comparing Bcl-6 expression and prognostic parameters in NHL group.
Parameter Bcl-6 positive Bcl-6 negative P Significance
N. cases % cases N. cases % cases
Age (mean) ≥45 yrs 0028 73.7 0.001 S
<45 yrs 6 100 10 26.3
Sex (mean) M233.5 24 63.2 0.167 NS
F4 66.5 14 36.8
Hb g/dL (mean) ≥10 2 33.5 20 52.6 0.38 NS
<10 4 66.5 18 47.4
Plt ﾥ109/L (mean) ≥150  6 100 20 52.6 0.028 S
<150  0018 47.4
TLC ﾥ109/L (mean) ≥8  2 33.5 12 31.6 0.932 NS
<8  4 66.5 26 68.4
LDH IU/L (mean) ≥500  4 66.5 22 57.9 0.685 NS
<500  2 33.5 16 42.1
Stage I233.5 4 10.5 0.388 NS
II 00 6 15.8
III 2 33.5 12 31.6
IV 2 33.5 16 42.1
Pattern  Diffuse  006 15.8 0.26 NS
Patchy  2 33.5 12 31.6
Interstitial  008 21.0
Mixed  4 66.5 12 31.6
Therapeutic Responders 4 66.5 16 42.1 0.26 NS
response Non-responders 2 33.5 22 57.9
Clinical Complete remission 6 100 18 47.4 0.016 S
outcome Relapse  0020 52.6
Fate  Alive  6 100 25 78.9 0.088 NS
Death  0013 21.1
S, significant, NS, non-significant. TLC, total leukocytic count; Hb, hemoglobin; Plts, platelets; BML, bone marrow lymphocytes; LDH, lactate
dehydrogenase; Unfavorable = survival ≤ 12 months, Favorable = survival > 12 months.
Figure  3.  Bcl-6  positivity  in  a  case  of
DLBCL (x40).
Figure 1. Bcl-2 positivity in a case of follic-
ular lymphoma (A): x40. 
Figure 2. Bcl-2 positivity in a case of follic-
ular lymphoma (B): x10
Figure 4. Kaplan-Meier overall survival and disease-free survival times in relation to
Bcl-2 protein expression.[Hematology Reports 2011; 3:e26]
rate was 44% in Bcl-2 positive patients com-
pared to 85% in negative cases (log rank 8.7;
P=0.003) and DFS rate was 12% versus 64%
(log rank, 19.13; P=0.001) (Figure 3).
Relation of Bcl-6 protein
expression to clinical and
laboratory prognostic factors
A  statistically  significant  difference
(P=0.001)  was  detected  among  the  studied
patients as regards age in which all the Bcl-6
positive cases were below the age of 45 years.
In  addition,  a  statistically  significant  differ-
ence was also obtained (P=0.028) in platelet
count in which all Bcl-6 positive cases had a
normal platelet count. No statistically signifi-
cant  difference  was  seen  as  regards  other
prognostic  factors  (P>0.05)  (Table  3  and
Figure 2).
Impact of Bcl-6 protein expression
on response to therapy and clinical
outcome
No  statistically  significant  difference
(P>0.05)  was  detected  among  patients  with
positive  Bcl-6  protein  expression  as  regards
response to the therapeutic regimens adopted
and mortality rates. However, a significantly
lower  relapse  rate  was  detected  in  patients
with  positive  Bcl-6  protein  than  in  patients
with negative expression (P=0.016).
Bcl-6 expression in relation to
patients’ survival
As regards Bcl-6 expression, results of sur-
vival  analysis  were  consistent  among  Bcl-6
positive  and  negative  patients  (P>0.05).
Nevertheless,  OS  and  DFS  were  higher  in
patients exhibiting this marker (OS 100% ver-
sus 79% and DFS 66% versus 45%) (Figure 4). 
Discussion
Several prognostic parameters were used in
B-NHL to detect patients' outcome. To detect
the value of Bcl-2 and Bcl-6 in diagnosis and
prognosis of such diseases, immunostaining
of  Bcl-2  and  Bcl-6  was  performed  for  44
patients with B-NHL. In this study, using a cut
off 20% or more, Bcl-2 protein was positive in
36.4% (16 of 44) of NHL cases (62.5% of FL,
16.7% of MCL and 30% of DLBCL cases). 
Studying  Bcl-2  in  lymphoma  cases,
Papakonstantinous  et  al.15 proved  that  the
expression of Bcl-2 protein is not restricted to
B-cell  lymphomas  bearing  the  t(14;  18)
translocation  and  they  showed  the  complete
absence  of  any  correlation  between  BCL-2
gene  rearrangements  and  Bcl-2  protein
expression in NHL. Ben-Ezra and King16 have
suggested that Bcl-2 alone is useful in discrim-
inating FL and benign lymphoid aggregates. In
spite of the fact that the absence of Bcl-2 was
highly  specific  for  benign  lymphoid  aggre-
gates, the expression of Bcl-2 in some benign
and atypical lymphoid aggregates in the study
by West et al.17 did not make Bcl-2 a specific
marker for the detection of FL in bone marrow
biopsy specimens. In addition, Llanos et al.18
stated that Bcl-2 expression is related to the
grade of FL being highest in grade I and lowest
in grade III, which matches with our negative
cases where 5 of 6 of our negative Bcl-2 FL
cases were of grade III.
The  percentage  of  positive  Bcl-2  in  MCL
cases was surprisingly low (16.7%). In fact, our
negative  MCL  cases  gave  minimal  positivity
ranging from 5 to 20%; yet we considered them
negative  results  according  to  the  previously
agreed cut off. Navratile et al.19 also found that
Bcl-2 is expressed in low grade but not high
grade lymphoma, and although MCL looks like
a  slow  growing,  low-grade  tumor  under  the
microscope, it grows fast and behaves like a
high-grade lymphoma. 
Bcl-2 protein expression was studied in rela-
tion  to  treatment  response  and  clinical  out-
come,  revealing  a  statistical  significance,
where a high tendency for developing resist-
ance and a poor clinical outcome with signifi-
cantly shorter OS and DFS were shown in Bcl-
2  positive  compared  to  negative  patients.
Comparing Bcl-2 to prognostic parameters in
the NHL group in the current study, there was
a significantly higher LDH level and a signifi-
cantly  lower  platelet  count  in  Bcl-2  positive
NHL cases. 
Hadzi-Pecova  and  his  co-workers20 con-
firmed that the expression of Bcl-2 protein is
significantly  present  in  advanced  compared
with early stages of B-cell lymphoma. Similarly,
high Bcl-2 expression by Hermine et al.21 was
more frequently associated with stages III and
IV. However, according to Hadzi-Pecova et al.,20
Bcl-2 expression did not show any significant
influence either on total survival or on disease-
free survival.
Although some reports failed to show any
impact of Bcl-2 protein expression on survival
of DLBCL cases,22,23 subsequent studies have
reported that Bcl-2-positive cases have a worse
disease-free survival.24 Recently, Hallack Neto
et al.25 found a prognostic significance for Bcl-
2 protein regarding overall survival.
Llanos et al.18 found no significant differ-
ences regarding the prognostic effect of Bcl-2
expression between FL patient groups. On the
contrary, they observed a trend toward poorer
survival among DLBCL patients with high Bcl-
2 expression. Moreover, Iqbal et al.4 specified
that Bcl-2 expression is associated with poor
survival in the activated B cell-like subgroup of
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Figure 5. Kaplan-Meier overall survival and disease-free survival times in relation to
Bcl-6 protein expression.[page 84] [Hematology Reports 2011; 3:e26]
DLBCL but not in the germinal center B-cell
subgroup.  As  for  Bcl-6,  the  current  study
showed positivity in 13.6% (6 of 44) of NHL
cases  (11.1%  of  MCL  and  40%  of  DLBCL
cases). Despite the fact that FL usually stains
Bcl-6 positive in lymph nodes, bone marrow
lymphoid aggregates are less likely to express
Bcl-6 as experienced by West et al.. In their
study, only 12 out of 26 FL cases (i.e. 46%)
were positive for Bcl-6 in their bone marrow
specimens.  They  gave  two  explanations  for
this referring either to the nature of FL or the
micro-environment of the bone marrow.17
All Bcl-6 positive cases were below the age
of 45 years and had a normal platelet count.
The current study found no relation between
therapeutic response, OS and DFS on the one
hand, and Bcl-6 expression on the other hand.
However, a significantly lower relapse rate was
found in patients with positive Bcl-6 protein.
Some authors suggested expression of Bcl-6
to be a prognostic marker in DLBCL26-28 but
others have contradicted this.7,29,30 These dif-
ferences may partly be explained by the differ-
ences in the cut off value (10-30%) for a posi-
tive staining in these studies. Also, differences
in staining techniques may be of importance,
for instance, in one study using the EnVision
method and a low cut off of 10%, as much as
97% of cases were found positive for Bcl-6.9
Expression  of  Bcl-6  by  Holler  et  al.8 had
identified  prognostically  relevant  favorable
subgroups.  Also  Lossos  et  al.27 observed  a
strong predictive value for survival. In a study
by Colomo et al.,30 Bcl-6 was expressed in 91%
of DLBCL cases (23% Bcl-6 alone and 49% with
other  markers).  The  group  of  patients  with
restricted expression of Bcl-6 presented with
earlier stage, low-risk IPI and normal LDH val-
ues. However, although this group of patients
had the highest overall survival rate, the differ-
ence did not reach statistical significance. The
reasons for these discordant results in differ-
ent studies are not clear but they may be relat-
ed in part to the heterogeneity of the selected
patients. The aberrant expression of Bcl-6 in
MCL found in the current study was also expe-
rienced by some authors. Only one of 20 MCL
cases studied by Chuang et al.31 expressed Bcl-
6. Similarly, Gualco et al.32 found Bcl-6 expres-
sion in 12% of the MCL cases.
In conclusion, Bcl-2 and Bcl-6 are found fre-
quently in B-NHL and both proteins should be
considered as reliable prognostic markers. Bcl-
2 positive patients were associated with poor
prognosis as well as short OS and DFS times
whereas Bcl-6 positive patients were associat-
ed with a favorable prognosis. This indicated
their potential as promising targets for thera-
peutic  intervention.  However,  prospective
studies  with  more  patients  in  each  group
together with a longer follow up are recom-
mended.
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